Wechselwirkungen · Myclausen
Myclausen 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-212959 · Präparat HOS-155006
Aciclovir Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. The changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics (MPAG increased by 8 %) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage 3d0fca8f60039ebbd82046cc8491c61bcfb4c3b127b636ea4caf0a30fb6626df · Zeichen 0–652 im Abschnitt